ARCHIVES

ODAC Says Clear Clinical Benefit Required When Sponsors Claim Progression Delay

This article is from The Cancer Letter archive.

Vol. 35 No. 28 | July 17, 2009

Download PDF Visit The Full Archive

Related Articles

Therapeutic Modalities Improve Patient Quality of Life In Trials

February 27, 2004

In Brief: Broder Wins ARC’s Griffuel Prize; Lawyers Trained To Help Low-Income Breast Ca, Patients

October 16, 1992

FOLFOX 4 Should Be First-Line Therapy For Advanced Disease, NCCTG Finds

December 26, 2003

100 NSABP Sites May Enroll Patients; Only One Trial Open

July 15, 1994

NCI TO Issue RFA For Gene Therapy Studies; $20 Mil. Se-Aside Ok’d

January 10, 1992

T-Cell Vaccines Cut Time To Protective Immunity

November 25, 2005